These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11906957)

  • 21. Hippocampal SSTR4 somatostatin receptors control the selection of memory strategies.
    Gastambide F; Viollet C; Lepousez G; Epelbaum J; Guillou JL
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):153-63. PubMed ID: 18521573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
    Schmid HA; Silva AP
    J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin receptor subtype-5 mediates inhibition of peptide YY secretion from rat intestinal cultures.
    Chisholm C; Greenberg GR
    Am J Physiol Gastrointest Liver Physiol; 2000 Nov; 279(5):G983-9. PubMed ID: 11052995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2.
    Sharif N; Gendron L; Wowchuk J; Sarret P; Mazella J; Beaudet A; Stroh T
    Endocrinology; 2007 May; 148(5):2095-105. PubMed ID: 17272399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
    Shimon I
    Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of submucosal 5-HT(3) receptors elicits a somatostatin-dependent inhibition of ion secretion in rat colon.
    Yang N; Liu SM; Zheng LF; Ji T; Li Y; Mi XL; Xue H; Ren W; Xu JD; Zhang XH; Li LS; Zhang Y; Zhu JX
    Br J Pharmacol; 2010 Apr; 159(8):1623-5. PubMed ID: 20233224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo.
    Mroz MS; Keating N; Ward JB; Sarker R; Amu S; Aviello G; Donowitz M; Fallon PG; Keely SJ
    Gut; 2014 May; 63(5):808-17. PubMed ID: 23916961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists.
    Yang L; Guo L; Pasternak A; Mosley R; Rohrer S; Birzin E; Foor F; Cheng K; Schaeffer J; Patchett AA
    J Med Chem; 1998 Jun; 41(13):2175-9. PubMed ID: 9632348
    [No Abstract]   [Full Text] [Related]  

  • 30. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
    Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
    Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boosting bioavailability of topotecan: what do we gain?
    Hudes G
    J Clin Oncol; 2002 Jul; 20(13):2918-9. PubMed ID: 12089219
    [No Abstract]   [Full Text] [Related]  

  • 32. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of ANP secretion by somatostatin through somatostatin receptor type 2.
    Gao S; Oh YB; Shah A; Park WH; Kim SH
    Peptides; 2011 Jun; 32(6):1179-86. PubMed ID: 21539874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes.
    Banno Y; Sasaki S; Kamata M; Kunitomo J; Miyamoto Y; Abe H; Taya N; Oi S; Watanabe M; Urushibara T; Hazama M; Niwa SI; Miyamoto S; Horinouchi A; Kuroshima KI; Amano N; Matsumoto SI; Matsunaga S
    Bioorg Med Chem; 2017 Nov; 25(21):5995-6006. PubMed ID: 28988629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus.
    Kumar U
    J Comp Neurol; 2007 Sep; 504(2):185-205. PubMed ID: 17626271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin receptor subtypes 2 and 5 mediate inhibition of egg yolk-induced gall bladder emptying in mice.
    Kaczmarek P; Singh V; Cashen DE; Yang L; Berk S; Pasternak A; Xiong Y; Shen DM; Hutchins SM; Chapman K; Wiedenmann B; Schaeffer JM; Strowski MZ
    Neurogastroenterol Motil; 2010 Feb; 22(2):204-9, e66. PubMed ID: 19754922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin increases voltage-gated K+ currents in GH3 cells through activation of multiple somatostatin receptors.
    Yang SK; Parkington HC; Blake AD; Keating DJ; Chen C
    Endocrinology; 2005 Nov; 146(11):4975-84. PubMed ID: 16081634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
    J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
    Tulipano G; Bonfanti C; Milani G; Billeci B; Bollati A; Cozzi R; Maira G; Murphy WA; Poiesi C; Turazzi S; Giustina A
    Neuroendocrinology; 2001 May; 73(5):344-51. PubMed ID: 11399907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.